Steven Edelman, MD
Internal Medicine · San Diego, CANPI 1477585248
Payments from drug & device makers
Across 508 payments — averaging $1698.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$394K
- Lexicon Pharmaceuticals, Inc.$68K
- Lilly USA, LLC$58K
- Medtronic$54K
- AstraZeneca$43K
- Eli Lilly$40K
- plus $206K from 24 others
Across 24 payments — averaging $430.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$10K
- Dexcom, Inc.$273
What the payments were for
- Royalty or licence$41,0695%
- Consulting fees$378,17444%
- Speaking & faculty fees$331,19638%
- Travel & lodging$96,14611%
- Food & beverage$10,0921%
- Education$730%
- Gifts$590%
- Charitable contribution$2,2500%
- Other$3,8220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 169 | $394,074 |
| Lexicon Pharmaceuticals, Inc. | 11 | $67,889 |
| Lilly USA, LLC | 67 | $58,017 |
| Medtronic(2 entities) | 16 | $54,315 |
| AstraZeneca | 44 | $42,816 |
| Eli Lilly | 70 | $40,188 |
| Embecta Corp. | 16 | $38,679 |
| Xeris Pharmaceuticals, Inc. | 22 | $31,277 |
| Lifescan, Inc. | 5 | $30,485 |
| Mannkind Corporation | 14 | $22,603 |
| Sanofi | 6 | $18,824 |
| Sanofi US Services Inc. | 3 | $13,752 |
| Merck | 7 | $13,665 |
| Ascensia Diabetes Care US Inc. | 7 | $8,935 |
| Johnson & Johnson | 5 | $6,008 |
| Vertex | 5 | $5,694 |
| Boehringer Ingelheim | 3 | $4,950 |
| Boehringer Ingelheim International GmbH | 2 | $3,716 |
| BD | 2 | $2,542 |
| Novo Nordisk | 13 | $2,484 |
| Dexcom, Inc. | 8 | $1,460 |
| Portola Pharmaceuticals, LLC | 1 | $104 |
| Companion Medical, Inc. | 1 | $100 |
| Amgen | 4 | $87 |
| Abbott | 1 | $62 |
| Astrazeneca UK Limited | 1 | $61 |
| BETA Bionics, Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$127,066
- SOLIQUA 100/33$108,071
- TZIELD$50,534
- SOTAGLIFLOZIN$49,268
- MOUNJARO$48,830
- InPen$43,046
- NO PRODUCT DISCUSSED$36,753
- OneTouch$26,235
- GVOKE PFS$23,375
- AFREZZA$22,297
- FARXIGA$22,251
- BYDUREON$15,892
- STEGLATRO$12,390
- TRULICITY$11,850
- JARDIANCE$8,631
- ZEPBOUND$8,450
- GVOKE HYPOPEN$7,868
- SAR439954$6,734
- INVOKANA$5,911
- EVERSENSE E3 SENSOR KIT - RETAIL$5,000
How this compares
$862,882 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 18 | $31,690 |
| TrulicityDulaglutide | 24 | $31,597 |
| FarxigaDapagliflozin Propanediol | 23 | $31,540 |
| JardianceEmpagliflozin | 17 | $25,776 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $13,770 |
| OzempicSemaglutide | 11 | $9,914 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,678 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $4,345 |
| HumalogInsulin Lispro | 11 | $3,482 |
| Novolog FlexpenInsulin Aspart | 13 | $2,384 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,023 |
| Metformin Hcl ErMetformin Hcl | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Humalog | $58,017 | $35,07935 claims |
| AstraZenecaFarxiga | $42,816 | $31,54023 claims |
| Boehringer IngelheimJardiance | $4,950 | $25,77617 claims |
| Novo NordiskOzempic | $2,484 | $9,91411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.